BioMarin Pharmaceutical Inc (NASDAQ:BMRN) plans to land $4 billion in revenue by 2027.
The company is targeting an adjusted operating margin of low-to-mid 40%’s (starting at 40% in 2026).
The new structure, announced at an investor event Wednesday, covers three key business units. They include skeletal conditions, enzyme therapies, and Roctavian — its hemophilia A gene therapy.
BioMarin has been implementing a $500 million “cost transformation program” to contribute to non-GAAP operating margin targets set for 2026 and beyond.
CEO Alexander Hardy highlighted five experimental programs through 2031 for Voxzogo beyond achondroplasia, a type of genetic condition that causes dwarfism.
Voxzogo sales reached $470 million in 2023. According to BioMarin, the drug could prove a $5 billion opportunity with a ...